Each tablet contains: NO - URIC 100 NO - URIC 300
Allopurinol 100 mg 300 mg
Properties and Mode of Actionpromptly lowers plasma urate and urinary uric acid concentrations; thus facilitating the dissolution of tophi and reducing the risk of acid calculi formation.
NO - URIC is allopurinol, the powerful inhibitor of xanthine oxidase enzyme responsible for the oxidation of xanthine and hypoxanthine to uric acid.
NO - URIC
NO - URIC represents the rational approach to long-term therapy of gout.
Primary hyperuricemia: idiopathic, Lesch-Nyhan syndrome.
Secondary hyperuricemia associated with myeloproliferative and lymphoproliferative disorders, haemolytic anemias, radiation therapy, cytotoxic drugs, thiazide diuretics and psoriasis.
Gouty nephropathy, tophaceous deposits, renal urate stones, impaired renal function.
Patients unresponsive to the uricosuric regimen.
Prophylaxis of uric acid and calcium oxalate calculi.
Dosage and Administrationan acute gouty attack is liable to occur.
To reduce this possibility an initial daily dose of 100 mg is increased at weekly intervals by 100 mg daily. Concurrent prophylactic therapy with colchicine or an anti - inflammatory agent is useful during the first two months, provided that the urine is made alkaline and the volume maintained high.
Early in therapy with NO - URIC,
NO - URIC is well-tolerated, particularly when taken after meals.
Moderate - Severe gout
Hyperuricemia with malignancy,
antineoplastic agents or radiotherapy
Children with hyperuricemia
associated with malignancy
|200 - 300 mg daily|
400 - 600 mg daily.
Initial dose : 200 - 800 mg daily for 2 - 3 days.
Maintenance: 300 - 400 mg daily.
150 - 300 mg daily depending on age.
Up to 300 mg may be taken as a single daily dose, but in case larger amounts are required, divided doses are then favoured.
Dosage in renal impairment:
If Creatinine clearance is 10 - 20 ml/min., the dose is 100 - 200 mg daily.
If Creatinine clearance is < 10 ml/min., the dose is not more than 100 mg daily.
Precautionsdosage must be reduced in patients with renal or hepatic impairment.
NO - URIC is of no help in acute gout where colchicine; or any other anti-inflammatory agent should be started with first.
NO - URIC
Studies in animals showed no adverse effects in pregnancy; however, NO -URIC should be only used where clearly needed and when potential benefits outweigh the unknown potential hazards to the fetus.
thus the dose of azathioprine or 6 - Mercaptopurine should be reduced to the quarter when the drugs are given concomitantly.
The metabolism of 6 - Mercaptopurine is inhibited by NO - URIC
NO - URIC may interfere with the hepatic inactivation of oral anticoagulants.
The uricosurics increase the renal excretion of alloxanthine; thus causing a reduction in the NO - URIC
effect. Conversely, NO - URIC may delay the elimination of probenecid and increase its concentration in plasma.
should be abandoned.
In patients who have exhibited serious adverse effect from the medication, in nursing mothers and in children without malignancy, NO-URIC
A cutaneous reaction in the form of pruritic, maculopapular, urticarial, purpuric or exfoliative eruption may occur, more frequently with renal failure and require withdrawal of NO - URIC.
Other undesirable effects as nausea, vomiting, diarrhoea, abdominal pain or headache occasionally occur but usually do not require that NO - URIC be stopped.
NO - URIC 100 Tablets : Box of 5 strips of 10 tablets each.
NO - URIC 300 Tablets : Box of 2 strips of 10 tablets each.